Parliamentary Search

Written question asked by Lord Mendelsohn (Labour) on Wednesday, 11 May 2022, in the House of Lords. It was due for an answer on Wednesday, 25 May 2022. It was answered by Lord Kamall (Conservative) on Thursday, 16 June 2022 on behalf of the Department of Health and Social Care.

Tixagevimab/cilgavimab

Question

To ask Her Majesty's Government, further to the Written Answer by the Parliamentary Under-Secretary of State for the Department of Health and Social Care on 20 April (151279), what estimate they have made of when the UK Health Security Agency (UKHSA) will complete the testing of Evusheld against Omicron sub-variants; and why this has taken longer to complete than in (1) the US, and (2) the EU.

Original answer

AstraZeneca commissioned the UK Health Security Agency (UKHSA) to complete testing as part of studies into the effectiveness of Evusheld against Omicron variants. Initial data has been shared with AstraZeneca and testing continues for the Omicron variant BA.4. As timing of the results are dependent on a number of factors, we are currently unable to confirm the date of completion. AstraZeneca will review such data and determine whether further testing should be commissioned.

When undertaking testing, the UKHSA follows strict processes designed to ensure such treatments are effective. These processes may differ from regulations in other jurisdictions.

It has since been corrected.

Secondary information

Type
Written question
Reference
HL157
Session
2022-23
Related items
Tixagevimab/cilgavimab
Wednesday, 20 April 2022
Written questions
House of Commons
Correction to Written Parliamentary Questions
Monday, 17 April 2023
Written statements
House of Commons
Notes
Information corrected on 17 April at 731 c10-2WS
Subjects
Testing Tixagevimab/cilgavimab
Link
View this Written question on www.parliament.uk